摘要
目的 探讨P 170、GST、TOPO Ⅱ、nm2 3、CD44在骨肉瘤的表达及其与预后的关系。方法 15例骨肉瘤和 5例软骨肉瘤石蜡切片 ,应用S -P免疫组化染色 ,结合临床资料进行分析。结果 15例骨肉瘤P 170的阳性率为3 3 .3 3 % ,GST的阳性率为 80 % ,TOPO Ⅱ的阳性率为 46 .6 7% ,nm 2 3和CD44的阳性率分别为 93 .3 3 %、86 .6 7%。年龄小于 2 0岁的骨肉瘤患者组 ,P 170、TOPO Ⅱ、CD44的阳性率均高于年龄大于 2 0岁组 ,而nm2 3在小于 2 0岁组的阳性率却低于大于 2 0岁组 (P <0 .0 5 )。GST的表达率在两组无差异。术前化疗组P 170CD44nm2 3的阳性率高于术前无化疗组 ,而TOPO ⅡGST在术前化疗组的表达却低于术前无化疗组 (P <0 .0 5 )。存活在 2年以内者P 170 ,GST ,TOPO Ⅱ的阳性率比存活两年以上者高 ,而nm2 3、CD44的表达情况正相反 (P <0 .0 5 )。P 170、GST、TOPO Ⅱ、nm 2 3、CD44在骨肉瘤的表达率均高于软骨肉瘤 (P <0 .0 5 )。结论 P 170、GST、TOPO Ⅱ、nm 2 3、CD44在骨肉瘤的表达率明显高于软骨肉瘤。在骨肉瘤中P 170、GST、TOPO Ⅱ联合表达率越高 ,病人生存期越短。在临床上可联合检测 ,以此对骨肉瘤的恶性程度及预后进行评估。
? Objective The expression of P 170、GST、TOPO Ⅱ、nm23、CD44 in osteosarcoma was analyzed for approaching the relationship between the expression of the above 5 proteins and prognosis.Methods 18cases of human osteosarcoma and 5 cases of chondrosarcoma were studied by the methods of immunohistochemical assay.Results In osteosarcoma the positive rate was 33.3% for P 170,80% for GST and 46.67% for TOPO Ⅱ、 93.33% for nm23,and 86.67% for CD44.But in chondrosarcoma the positive rate of P 170 was 0, of GST was 20%,of TOPO Ⅱ was 20%,of CD44 and nm23 was 20% and 0 respectively.The positive rates of P 170,TOPO Ⅱ and CD44 in the group with the age of less than 20 were higher than those in the group of older than 20.P 170,CD44,nm23 more highly expressed in the group of preoperative chemotherapy than in the group of no preoperative chemotherapy.The patients survived for no more than 2 years had higher expressions of P 170、GST、TOPO Ⅱ.Conclusions Detection of P 170,GST,TOPO Ⅱ,nm23 and CD44 together can evaluate the malignance and prognosis of osteosarcoma,which should be used in clinic to instruct the treatment of osteosarcom. 〔
出处
《中国肿瘤临床与康复》
2000年第1期11-13,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
基金
吉林省科委基金资助项目(970329)
关键词
骨肉瘤
基因
免疫组化
osteosarcoma
gene
immunohistochemistry
